^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer

Published date:
01/27/2022
Excerpt:
Clinical investigations and Kaplan-Meier plotter analysis revealed that HBXIP is highly expressed in TamR breast cancer tissues. Furthermore, reinforced HBXIP expression associated with a high recurrence and poor relapse-free survival rates in tamoxifen monotherapy ER+ breast cancer patients.
DOI:
10.1016/j.jbc.2022.101644